Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines.
about
In vitro pharmacokinetics of anti-psoriatic fumaric acid estersB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsEfficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.Effects of monomethylfumarate on dendritic cell differentiation.Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cellsPharmacokinetics of oral fumarates in healthy subjects.German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).Psoriasis: emerging therapeutic strategies.Fumarate modulates the immune/inflammatory response and rescues nerve cells and neurological function after stroke in rats.Novel systemic therapies for the treatment of psoriasis.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Fumaric acid esters in dermatology.Dramatic improvement of psoriatic erythroderma after acute hepatitis: analysis of cytokine synthesis capability in peripheral blood T cells.German S3-guidelines on the treatment of psoriasis vulgaris (short version).Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.[S3-Guidelines for the therapy of psoriasis vulgaris].Fumaric acid esters in the management of psoriasis.Association of the interleukin-10 distal promoter (-2763A/C) polymorphism with late-onset psoriasis
P2860
Q24791666-9A2F0B82-E9BF-4114-88FA-DA3F47D0A195Q26770664-D2DAFBEF-F16F-40CE-A066-579CB615B0E1Q34046298-DC851D85-F6A7-43F1-80BD-B9159ADC3A4CQ34190076-6671ACE2-44BE-4CD2-9974-C5CBEBFF5A4AQ34564447-54A91D45-DDE9-472E-8463-0AFC4FD74A91Q35441339-EC535DA5-BC75-4D67-9A7C-CB142C2842B5Q35826385-3529A0FC-918D-480D-BDFB-5BE69580C27AQ35875481-07EEFB89-3A5A-4A8F-81EE-746D1C446CE9Q36028220-38CA88A2-9AFE-49F3-929D-9CAF92DAF9AFQ37336648-C1A2FFAD-3FB9-47DF-B0C0-CC8B4F50536FQ38628193-70CBAC06-9306-45BE-AD2D-68E5884C7FB0Q38831055-2EAC36E0-3F78-4591-A6C7-5423E5A47126Q42401921-C2C8873E-D3EB-4321-862A-47CB200D7E4DQ44541733-68BDEA3A-991E-4931-B594-6FF13E657DDFQ48480123-F9BDDB7B-EDB9-44B5-9702-1CD2BFEA330FQ48488976-66E9ABDF-F4D7-42BF-B731-6FDAC53D9640Q52888818-FAB4A79C-9353-424D-8963-25AFAE46F85DQ52925161-BACA9CC0-FAE3-488E-B65B-FEF8D61E083BQ52928363-33559D2E-87FA-4DB2-898E-061EFA1F5DD9Q54958047-7A29641A-5C17-4BD5-ABFB-2C1A51E1EC6AQ57002818-73C320B8-B722-430D-A6DF-579EEBBCE76F
P2860
Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@en
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@nl
type
label
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@en
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@nl
prefLabel
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@en
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@nl
P2093
P2860
P1476
Beneficial effects of fumarate ...... egulation of type 1 cytokines.
@en
P2093
Barrois AJ
Litjens NH
Nibbering PH
Rademaker M
Van De Meide PH
Van Den Oudenrijn AC
Van Dissel JT
Zomerdijk TP
P2860
P304
P356
10.1046/J.1365-2133.2003.05153.X
P407
P577
2003-03-01T00:00:00Z